Attralus

@Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus. Read the press release: attralus.com/press-releases…. #amyloidosis

Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at #ASH2025. Read the press release: attralus.com/press-releases… #amyloidosis

Attralus presents new Data on its pan-amyloid diagnostic imaging candidates at #ASNC2025. Read the press release: attralus.com/press-releases… #amyloidosis

Attralus presents new data on our pan-amyloid diagnostic candidates at #ACC2025. Read the press release: attralus.com/press-releases… #amyloidosis

Attralus announces enrollment of first patient in Phase 3 trial for the pan-amyloid diagnostic 124I-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases….

Attralus receives Orphan Drug Designation from @US_FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release: attralus.com/press-releases…

Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases….

Attralus receives EMA Committee for Orphan Medicinal Products positive opinions for AT-02 for treatment of both ATTR and AL #amyloidosis. Read the press release: attralus.com/press-releases…

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at #ISA2024. Read the press release at attralus.com/press-releases…. #amyloidosis

Looking forward to @ISA_Amyloidosis #ISA_2024 in Rochester, MN on 26-30 May. We are proud to announce 16 presentations, incl 3 oral presentations, highlighting our investigational agents and continued commitment to #amyloidosis patients. Learn more: attralus.com.

On #raredisease day we honor rare disease patients waiting for new treatments, the patient advocacy groups and healthcare providers working tirelessly to improve patients' lives, and especially the many #amyloidosis patients as they battle with this rare and devastating disease.

We are excited to announce the closing of our $56 million financing. Read more: attralus.com/press-releases… #amyloidosis

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging) #JACCIMG Read more - attralus.com/press-releases… #amyloidosis

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023 Read more - attralus.com/press-releases… #amyloidosis

For #NationalAmyloidosisDay, a reminder that #amyloidosis is a #raredisease that is progressive and debilitating, and as many as 80% of patients worldwide go undiagnosed or wait years to receive a diagnosis. Learn more about systemic #amyloidosis @ ow.ly/62CK50J2aZ1.

New ways to target pathologic tau focus on intracellular tau, vaccines, and multivalent molecules that attack several types of fibril. #alzheimersdisease ow.ly/YgGo50Ofh39

Attralus' experimental therapies, AT-04 and AT-07, are able to bind to proteins causing toxic clumps in Parkinson's, suggesting new treatment possibilities. buff.ly/3nSvs7V #parkinsonsdiseaseresearch #parkinsonsdisease #livingwithparkinsons

Informative video from Dr. Jonathan Wall of @attralus describing their work to develop non-invasive imaging to diagnose amyloid deposits. Great stuff. #amyloidosis youtube.com/watch?v=7hDLbR…

New preclinical data on AT-04 and AT-07, our pan-amyloid removal therapeutics targeting neurodegenerative disorders was presented this past weekend at #ADPD2023. Read more attralus.com/press-releases… #amyloidosis #AlzheimersDisease

Living with systemic #amyloidosis is challenging, and while every patient is unique, they are certainly not alone. Visit @AmyloidosisSupp to find a patient support group in your area. Learn more at amyloidosissupport.org. #AmyloidosisAwarenessMonth